Doctoral defense Matt Maurer

The Department of Clinical Medicine, Aalborg University and The Department of Hematology, Aalborg University Hospital are pleased to invite to doctoral defense by Matthew J. Maurer, who will defend the thesis entitled: Dynamic Prognosis and Clinical Outcomes in Lymphoma during the Rituximab Era

Tidspunkt

27.01.2021 kl. 14.00 - 20.00

Beskrivelse

The defense will take place

Wednesday January 27th, 2021, at 2 pm

Due to covid-19 and anticipated travel restrictions between the United States and Denmark, the defense will be held virtually via Zoom. Sign up by e-mail to inst.klinisk.phd@dcm.aau.dk

Assessment Committee

Professor Josee M Zijlstra
University Medical Center, Amsterdam, The Netherlands

Professor Paul W. Dickman
Karolinska Instituttet, Stockholm, Sweden

Professor Jeppe Hagstrup Christensen (Chairman)
Aalborg University, Aalborg, Denmark

About the dissertation

This dissertation evaluates clinical outcomes and applications in the setting of lymphoma. The risk of relapse and subsequent outcome is examined in several lymphoma subtypes, taking concepts beyond the time of diagnosis and into the period of clinical follow-up, in particular via event-free survival at 24 months (EFS24). Outcomes are benchmarked against the background population to provide a reference for patients who may be in a cured state or conversely identify high risk subsets of patients. These findings are then extended into development of risk calculators as well as clinical trial design and interpretation. The work presented in this dissertation has impacted clinical management, study design and interpretation in the field of lymphoma, as well as provided important tools for patients and clinicians to better understand risk and prognosis in the current treatment era.

In the past years, Matthew J. Maurer has been collaborating extensively with the Department of Hematology, Aalborg University Hospital on several epidemiology and real-world evidence projects related to the real-world outcomes in lymphoma and development of prognostics models, including a number of ongoing international multicenter studies